Tests olomorasib with immunotherapy for KRAS G12C lung cancer
Tests olomorasib with immunotherapy in adults with KRAS G12C non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Key facts
- Where
- Amsterdam, Breda, Harderwijk, Maastricht, Tilburg, Utrecht, and Zwolle, NetherlandsSee the 8 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with KRAS G12C-mutant non-small cell lung cancer, either after surgery (Part A) or not removable by surgery (Part B).
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Part A: stage II-IIIB after surgery. If chemo-immunotherapy was given before surgery, some tumor must remain; no complete response. Part B: stage III cancer that cannot be removed by surgery and has not grown during chemoradiotherapy.
- Earlier treatment
- Part A: chemo-immunotherapy before surgery, or surgery first. Part B: platinum-based chemoradiotherapy given at the same time, with no growth of the cancer.
- Biomarker or test result
- KRAS G12C mutation in the tumor. PD-L1 level must be known.
Main reasons for not taking part
- Known EGFR or ALK gene changes that can be treated with targeted drugs
- Another cancer that is growing or needed treatment in the past 2 years
- Autoimmune disease needing treatment of the whole body in the past 2 years
- Serious (Grade 3 or higher) side effect or allergic reaction from earlier immunotherapy
- Breastfeeding during treatment
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
Source: NCT06890598, who can take part
Where in Netherlands
- Amsterdam UMC Locatie VUMCAmsterdam, NetherlandsTaking people
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)Amsterdam, NetherlandsTaking people
- Amphia Ziekenhuis - Locatie Breda MolengrachtBreda, NetherlandsTaking people
- Ziekenhuis St JansdalHarderwijk, NetherlandsTaking people
- Maastricht UMCMaastricht, NetherlandsNot yet recruiting
- ETZ ElisabethTilburg, NetherlandsTaking people
- St. Antonius Ziekenhuis, locatie UtrechtUtrecht, NetherlandsTaking people
- Isala, locatie ZwolleZwolle, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06890598EU 2024-512302-25-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.Read full original descriptionShow less
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Inclusion: Histological or cytological confirmation of NSCLC; Part A; Clinical Stage II-IIIB (N0, N1, N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible; Pathologic Stage II-IIIB (N0, N1, N2) NSCLC treated with initial upfront resection; Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy; Must have disease with evidence of KRAS G12C mutation; Must have known programmed death-ligand 1 (PD-L1) expression; Must have an ECOG performance status of 0 or 1; Able to swallow oral medication; Must have adequate laboratory parameters; Contraceptive use should be consistent with local regulations for those participating in clinical studies; Women of childbearing potential must; Have a negative pregnancy test; Not be breastfeeding during treatment.
Exclusion: Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy; Have another type of cancer that is progressing or required active treatment within the past 2 years before screening; Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed; Have known, actionable changes in the EGFR or ALK genes.